Abraham Ceesay's most recent trade in Rapport Therapeutics Inc. was a trade of 5,833 Common Stock done at an average price of $26.1 . Disclosure was reported to the exchange on Jan. 20, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Rapport Therapeutics Inc | Abraham N. Ceesay | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 26.12 per share. | 20 Jan 2026 | 5,833 | 562,080 | - | 26.1 | 152,333 | Common Stock |
| Rapport Therapeutics Inc | Abraham N. Ceesay | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 26.11 per share. | 20 Jan 2026 | 5,083 | 25,812 | - | 26.1 | 132,737 | Common Stock |
| Rapport Therapeutics Inc | Abraham N. Ceesay | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 30.04 per share. | 17 Dec 2025 | 2,792 | 568,513 | - | 30.0 | 83,862 | Common Stock |
| Rapport Therapeutics Inc | Abraham N. Ceesay | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 28.84 per share. | 17 Dec 2025 | 2,441 | 571,305 | - | 28.8 | 70,393 | Common Stock |
| Rapport Therapeutics Inc | Abraham N. Ceesay | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 30.04 per share. | 17 Dec 2025 | 2,421 | 31,410 | - | 30.0 | 72,722 | Common Stock |
| Rapport Therapeutics Inc | Abraham N. Ceesay | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 28.84 per share. | 17 Dec 2025 | 2,147 | 33,831 | - | 28.8 | 61,925 | Common Stock |
| Rapport Therapeutics Inc | Abraham N. Ceesay | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 31.04 per share. | 17 Dec 2025 | 600 | 567,913 | - | 31.0 | 18,622 | Common Stock |
| Rapport Therapeutics Inc | Abraham N. Ceesay | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 31.04 per share. | 17 Dec 2025 | 515 | 30,895 | - | 31.0 | 15,985 | Common Stock |
| Rapport Therapeutics Inc | Abraham N. Ceesay | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 25.43 per share. | 17 Nov 2025 | 3,056 | 573,746 | - | 25.4 | 77,715 | Common Stock |
| Rapport Therapeutics Inc | Abraham N. Ceesay | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 25.44 per share. | 17 Nov 2025 | 2,841 | 35,978 | - | 25.4 | 72,267 | Common Stock |
| Rapport Therapeutics Inc | Abraham N. Ceesay | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 24.92 per share. | 17 Nov 2025 | 2,777 | 576,802 | - | 24.9 | 69,216 | Common Stock |
| Rapport Therapeutics Inc | Abraham N. Ceesay | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 24.91 per share. | 17 Nov 2025 | 2,242 | 38,819 | - | 24.9 | 55,850 | Common Stock |
| Rapport Therapeutics Inc | Abraham N. Ceesay | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 25.72 per share. | 15 Oct 2025 | 4,647 | 580,765 | - | 25.7 | 119,539 | Common Stock |
| Rapport Therapeutics Inc | Abraham N. Ceesay | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 25.75 per share. | 15 Oct 2025 | 4,328 | 41,816 | - | 25.7 | 111,429 | Common Stock |
| Rapport Therapeutics Inc | Abraham N. Ceesay | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 26.14 per share. | 15 Oct 2025 | 1,186 | 579,579 | - | 26.1 | 31,001 | Common Stock |
| Rapport Therapeutics Inc | Abraham N. Ceesay | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 26.17 per share. | 15 Oct 2025 | 755 | 41,061 | - | 26.2 | 19,760 | Common Stock |
| Rapport Therapeutics Inc | Abraham N. Ceesay | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 26.30 per share. | 17 Sep 2025 | 39,435 | 586,812 | - | 26.3 | 1,037,101 | Common Stock |
| Rapport Therapeutics Inc | Abraham N. Ceesay | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 26.30 per share. | 17 Sep 2025 | 34,885 | 46,844 | - | 26.3 | 917,542 | Common Stock |
| Rapport Therapeutics Inc | Abraham N. Ceesay | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 26.87 per share. | 17 Sep 2025 | 1,400 | 585,412 | - | 26.9 | 37,624 | Common Stock |
| Rapport Therapeutics Inc | Abraham N. Ceesay | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 27.04 per share. | 17 Sep 2025 | 700 | 46,144 | - | 27.0 | 18,930 | Common Stock |
| Pacira BioSciences Inc | Abraham N. Ceesay | Director | Sale of securities on an exchange or to another person at price $ 27.19 per share. | 04 Sep 2025 | 2,354 | 9,039 (0%) | 0% | 27.2 | 64,005 | Common Stock |
| Pacira BioSciences Inc | Abraham N. Ceesay | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2025 | 11,279 | 11,279 | - | - | Stock Option (Right to Buy) | |
| Pacira BioSciences Inc | Abraham N. Ceesay | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2025 | 6,163 | 11,393 (0%) | 0% | 0 | Common Stock | |
| Rapport Therapeutics Inc | Abraham N. Ceesay | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 428,000 | 428,000 | - | - | Stock Option (Right to Buy) | |
| Pacira BioSciences Inc | Abraham N. Ceesay | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2024 | 12,179 | 12,179 | - | - | Stock Option (Right to Buy) | |
| Pacira BioSciences Inc | Abraham N. Ceesay | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2024 | 5,230 | 5,230 (0%) | 0% | 0 | Common Stock | |
| Rapport Therapeutics Inc | Abraham N. Ceesay | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2024 | 530,647 | 530,647 | - | - | Stock Option (Right to Buy) | |
| Cerevel Therapeutics Holdings | Abraham Ceesay | President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2023 | 114,445 | 114,445 | - | - | Stock Option (Right to Buy) | |
| Cerevel Therapeutics Holdings | Abraham Ceesay | President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2023 | 29,083 | 29,083 | - | - | Restricted Stock Units | |
| Cerevel Therapeutics Holdings | Abraham Ceesay | President | Sale of securities on an exchange or to another person at price $ 32.50 per share. | 08 Sep 2022 | 19,210 | 0 | - | 32.5 | 624,325 | Common Stock |
| Cerevel Therapeutics Holdings | Abraham Ceesay | President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Sep 2022 | 19,210 | 365,009 | - | - | Stock Option (Right to Buy) | |
| Cerevel Therapeutics Holdings | Abraham Ceesay | President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.17 per share. | 08 Sep 2022 | 19,210 | 19,210 | - | 13.2 | 252,996 | Common Stock |
| Cerevel Therapeutics Holdings | Abraham Ceesay | President | Sale of securities on an exchange or to another person at price $ 32.50 per share. | 22 Aug 2022 | 9,605 | 0 | - | 32.5 | 312,163 | Common Stock |
| Cerevel Therapeutics Holdings | Abraham Ceesay | President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Aug 2022 | 9,605 | 384,219 | - | - | Stock Option (Right to Buy) | |
| Cerevel Therapeutics Holdings | Abraham Ceesay | President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.17 per share. | 22 Aug 2022 | 9,605 | 9,605 | - | 13.2 | 126,498 | Common Stock |
| Cerevel Therapeutics Holdings | Abraham Ceesay | President | Sale of securities on an exchange or to another person at price $ 34.12 per share. | 15 Aug 2022 | 9,606 | 0 | - | 34.1 | 327,757 | Common Stock |
| Cerevel Therapeutics Holdings | Abraham Ceesay | President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Aug 2022 | 9,606 | 393,824 | - | - | Stock Option (Right to Buy) | |
| Cerevel Therapeutics Holdings | Abraham Ceesay | President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.17 per share. | 15 Aug 2022 | 9,606 | 9,606 | - | 13.2 | 126,511 | Common Stock |
| Cerevel Therapeutics Holdings | Abraham Ceesay | President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.17 per share. | 05 Aug 2022 | 38,424 | 38,424 | - | 13.2 | 506,044 | Common Stock |
| Cerevel Therapeutics Holdings | Abraham Ceesay | President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Aug 2022 | 38,424 | 422,641 | - | - | Stock Option (Right to Buy) | |
| Cerevel Therapeutics Holdings | Abraham Ceesay | President | Sale of securities on an exchange or to another person at price $ 32.50 per share. | 05 Aug 2022 | 38,424 | 0 | - | 32.5 | 1,248,780 | Common Stock |
| Cerevel Therapeutics Holdings | Abraham Ceesay | President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Aug 2022 | 19,211 | 403,430 | - | - | Stock Option (Right to Buy) | |
| Cerevel Therapeutics Holdings | Abraham Ceesay | President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.17 per share. | 05 Aug 2022 | 19,211 | 19,211 | - | 13.2 | 253,009 | Common Stock |
| Cerevel Therapeutics Holdings | Abraham Ceesay | President | Sale of securities on an exchange or to another person at price $ 37.75 per share. | 05 Aug 2022 | 9,606 | 9,605 | - | 37.8 | 362,627 | Common Stock |
| Cerevel Therapeutics Holdings | Abraham Ceesay | President | Sale of securities on an exchange or to another person at price $ 39.50 per share. | 05 Aug 2022 | 9,605 | 0 | - | 39.5 | 379,398 | Common Stock |
| Cerevel Therapeutics Holdings | Abraham Ceesay | President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2021 | 461,065 | 461,065 | - | - | Stock Option (Right to Buy) |